| __timestamp | Celldex Therapeutics, Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 104381000 | 152500000 |
| Thursday, January 1, 2015 | 100171000 | 187800000 |
| Friday, January 1, 2016 | 102726000 | 184000000 |
| Sunday, January 1, 2017 | 96171000 | 167700000 |
| Monday, January 1, 2018 | 66449000 | 218600000 |
| Tuesday, January 1, 2019 | 42672000 | 187400000 |
| Wednesday, January 1, 2020 | 42534000 | 177700000 |
| Friday, January 1, 2021 | 53311000 | 122000000 |
| Saturday, January 1, 2022 | 82258000 | 123100000 |
| Sunday, January 1, 2023 | 118011000 | 122500000 |
Infusing magic into the data realm
In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Celldex Therapeutics, Inc. and Perrigo Company plc have demonstrated contrasting approaches to R&D investment.
From 2014 to 2023, Celldex Therapeutics, Inc. has shown a dynamic R&D spending pattern, peaking in 2014 and 2023 with expenditures around 118 million USD. This reflects a strategic focus on pioneering therapies, despite a dip in the mid-2010s. In contrast, Perrigo Company plc maintained a more stable R&D investment, with a notable peak in 2018, reaching approximately 219 million USD. This steady approach underscores Perrigo's commitment to incremental innovation in consumer healthcare.
These trends highlight the diverse strategies within the biopharma sector, where companies balance between breakthrough innovations and consistent product development.
Research and Development Investment: Eli Lilly and Company vs Perrigo Company plc
Research and Development Expenses Breakdown: Gilead Sciences, Inc. vs Perrigo Company plc
R&D Spending Showdown: BeiGene, Ltd. vs Celldex Therapeutics, Inc.
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Celldex Therapeutics, Inc.
Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Blueprint Medicines Corporation vs Celldex Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Grifols, S.A. and Celldex Therapeutics, Inc.
R&D Spending Showdown: Corcept Therapeutics Incorporated vs Celldex Therapeutics, Inc.
Research and Development: Comparing Key Metrics for PTC Therapeutics, Inc. and Perrigo Company plc
R&D Spending Showdown: Perrigo Company plc vs MannKind Corporation
Perrigo Company plc vs Wave Life Sciences Ltd.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.